• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

    0.9206 -0.0267 (-2.82%)
    Streaming Delayed Price Updated: 2:15 PM EDT, Jul 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 42,746
    Open 0.9269
    Bid (Size) 0.9206 (500)
    Ask (Size) 0.9351 (500)
    Prev. Close 0.9473
    Today's Range 0.9200 - 0.9500
    52wk Range 0.9000 - 2.450
    Shares Outstanding 41,876,087
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC
    From MIRA Pharmaceuticals
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy
    From MIRA Pharmaceuticals
    Via ACCESS Newswire

    Performance

    YTD
    -38.2%
    -38.2%
    1 Month
    -12.3%
    -12.3%
    3 Month
    -13.2%
    -13.2%
    6 Month
    -39.0%
    -39.0%
    1 Year
    -23.9%
    -23.9%

    More News

    Read More
    News headline image
    MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
    Via ACCESS Newswire
    Wondering what's happening in today's after-hours session? ↗
    Via Chartmill
    News headline image
    What's Going On With MIRA Pharma Stock Tuesday? ↗
    Via Benzinga
    News headline image
    MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
    Via ACCESS Newswire
    News headline image
    MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
    Via ACCESS Newswire
    News headline image
    12 Health Care Stocks Moving In Monday's After-Market Session ↗
    Via Benzinga
    News headline image
    MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
    Via ACCESS Newswire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    News headline image
    Mag 7 Undercard Stocks: PRSO, MIRA, WHWK, RDZN Surge on AI, Biotech, and Technology News – Full List Inside
    Via AB Newswire
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Which stocks are experiencing notable movement on Thursday? ↗
    Via Chartmill
    News headline image
    MIRA Pharmaceuticals Stock Surges Following Positive Preclinical Data ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Dow Dips Over 100 Points; US Crude Oil Inventories Surge ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Top movers analysis in the middle of the day on 2025-10-16: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings ↗
    Via Benzinga
    Topics Stocks
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
    Via ACCESS Newswire

    Frequently Asked Questions

    Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
    MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
    What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
    The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 0.9206
    When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 07/02/26 02:15 PM ET
    What is the market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock is 38.55M
    How many shares of MIRA Pharmaceuticals, Inc. - Common Stock are outstanding?
    MIRA Pharmaceuticals, Inc. - Common Stock has 39M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.